Abstract 21P
Background
Pathogenic mutations in the epigenetic modulator histone-lysine N-methyltransferase 2C (KMT2C) occur in up to 1 in every 6 breast cancers and KMT2C likely functions as a tumour suppressor. Despite this high frequency, therapeutic implications of deleterious KMT2C mutations are poorly understood and detailed pre-clinical work is still needed. DNA damage repair pathways may be affected by KMT2C mutations according to published preclinical data. The aim of this study is to identify the effects of KMT2C knockdown in vitro in breast cancer cells as a basis for identifying potential synthetic lethality drug targets.
Methods
MCF-7 (ER+ breast cancer) cells were cultured and 500,000 cells per well were plated on 6-well plates. KMT2C siRNA was transfected via Lipofectamine as per protocol in three wells, with universal control siRNA in three wells. Total RNA was extracted and sent for sequencing. RNA expression was quantified by RT-qPCR.
Results
RNA-seq confirmed reduction in expression of KMT2C in KMT2C siRNA-treated cells vs controls. RT-qPCR showed a reduction in expression of DNA damage repair genes including BRCA1 (RQ = 0.36), BRCA2 (RQ = 0.37), RAD51 (RQ = 0.36), RAD54L (RQ = 0.28) and POLD3 (RQ = 0.47).
Conclusions
KMT2C loss-of-function in breast cancer may impact DNA damage response pathways including homologous recombination and therefore be implicated in response to established treatments such as PARP-inhibitors. Further study including mapping of co-dependencies by whole genome siRNA screens in KMT2C-mutant breast cancer cells to identify synthetic lethality targets, as well as cell toxicity assays, are being performed in light of these results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beaumont RCSI Cancer Centre.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
46P - Effect of coadministration of antioxidant chlorophyllin with docetaxel on invasion and metastasis in triple-negative breast cancer in vivo/in vitro
Presenter: Ayse Burus
Session: Poster session 09
47P - An ozone delivery system by cisplatin prodrug self-assembling micelles combining microwave to sensitizing immune checkpoint inhibitor in triple-negative breast cancer
Presenter: Dan Zheng
Session: Poster session 09
48P - Non-steroid anti-inflammatory treatment enhances the efficacy of modulated electro hyperthermia on triple-negative breast cancer and melanoma cancer models in vivo
Presenter: Nino Giunashvili
Session: Poster session 09
49P - Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer
Presenter: Ana Julia de Freitas
Session: Poster session 09
50P - Application and mechanism of tarloxotinib in HER2-positive breast cancer
Presenter: Xinyi Shao
Session: Poster session 09
51P - Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic breast tumour therapy by glutamine deprivation and cascading thrombosis
Presenter: Liqiang Zhou
Session: Poster session 09
53P - Treatment of cancer cells based on circulating tumor cell’s expression profile using off-label drugs
Presenter: Panagiotis Apostolou
Session: Poster session 09
54P - Enhanced oxidative phosphorylation of metastasis-initiating cells facilitates esophageal tumor cell seeding in lymph nodes
Presenter: Shanshan Li
Session: Poster session 09
55P - Transcriptional profiles of engineered T cells stimulated with different receptor structures and co-stimulatory domains
Presenter: Ungue Shin
Session: Poster session 09
56P - SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume
Presenter: Christa Dijkhuizen
Session: Poster session 09